Serapha Bio

Emerged from stealth on June 23, 2026 with $230 million in committed financing. Lead program SERP-01 is an in vivo adenine base editing therapy delivered via lipid nanoparticles, targeting the SERPINA1 E342K point mutation that causes alpha-1 antitrypsin deficiency (AATD). The asset originated in China, has generated proof-of-concept data in human patients in Shanghai, and cleared FDA IND review in March 2026.